[1] Boolell V,Alamgeer M,Watkins DN,et al.The Evolution of Therapies in Non-Small Cell Lung Cancer[J].Cancers (Basel),2015,7(3):1815-1846.
[2] 韩啸东, 张侠, 刘畅, 等. 非小细胞肺癌患者血液高凝状态的临床调查[J].现代生物医学进展, 2015, 15(5): 882-887.
[3] 闫顺朝. 乳腺癌患者术前血清纤维蛋白原水平临床意义的探讨[J].现代肿瘤医学, 2015, 23(1): 51-54.
[4] Tas F, Kilic L, Serilmez M, et al. Clinical and prognostic significance of coagulation assays in lung cancer[J].Respir Med,2013, 107(3): 451-457.
[5] Trabjerg TB, Sander KD, Nybo M, et al. Coagulation and fibrinolysis during lung surgery:an experimental study[J].Int Card Thorac Surg,2014, 19(4): 567-571.
[6] Cui JS, Jing ZP, Zhuang SJ, et al. D-D as a biomarker for acute aortic dissection: a systematicreview and meta-analysis[J].Medicine(Baltimore),2015, 94(4): e471.
[7] Ge LP, Li J, Bao QL, et al. Prognostic and predictive value of plasma D-D in advanced non-small cell lung cancer patients undergoing first-line chemotherapy[J].Clin Transl Oncol,2015, 17(1): 57-64.
[8] 赵保平,张明智,陈曦.肺癌患者化疗前后凝血、纤溶功能及血小板参数的变化及其临床意义[J].肿瘤基础与临床,2015,28(2):150-153.
[9] 顾恒琼,苏 鑫,吴玄豪,等.血浆纤维蛋白原和 D-二聚体在老年 NSCLC 患者预后中的意义[J].现代生物医学进展,2017,27(17):5262-5266.
[10] 张雪,姜达,李颖.肿瘤相关性高凝的分子机制[J].国际肿瘤学杂志,2016,43(5):356-359.